Men With Breast Cancer Present at Later Stage, Have Worse Prognosis Than Women
At 10 years, the disease-free survival rate was 54.5%, and the overall survival rate was 50.7%.
Home
Induction Chemo Plus CRT More Effective Than CRT Alone in Nasopharyngeal Carcinoma
Induction chemotherapy was associated with improvements in disease-free, failure-free, relapse-free, and progression-free survival.
Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
Factors Associated With Non-Small Cell Lung Cancer Stage at Presentation
Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.
Breyanzi Approved as Second-Line Treatment for Large B-Cell Lymphoma
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
Dual Effect Identified for Arsenic in Carcinogenesis
The arsenic level in drinking water was negatively associated with incidences of lymphoma and leukemia in men and women.
Symptoms May Persist After Pediatric SARS-CoV-2 Infection
A large cross-sectional study offered a survey of long COVID symptoms in children who have been infected with SARS-CoV-2.
High-Deductible Health Plans Linked to Delayed Diagnosis of Metastatic Cancer
Having a high-deductible health plan was associated with a nearly 5-month delay in the diagnosis of metastatic cancer.
Rate of CRT-Related Pneumonitis in NSCLC May Be Higher in Real World Than in Clinical Trials
The pooled incidence of chemoradiation-induced grade 3-5 pneumonitis was 3.62% in randomized trials, 5.98% in observational studies, and 7.85% in observational studies of platinum doublet chemotherapy.
Denosumab Improves Long-Term Outcomes in AI-Treated Breast Cancer
Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2022
Loading... 
Loading...